GO:2000169Ontology (GO BP)GO biological process · ~11 member genes
Q-omics provides the Regulation of peptidyl-cysteine S-nitrosylation (GO:2000169) pathway profile, scoring each patient from the combined activity of its roughly 11 member genes. Pathway activity is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, the pathway is differentially active in 14, with the highest sampling consensus in HNSC. Additionally, pathway RNA activity shows 35,868 significant cross-omics associations, again with the highest sampling consensus in STAD. Together, these results highlight DLBC, HNSC, and STAD as cancer lineages where the pathway shows reproducible signals across outcome, tissue activity, and molecular association analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns. Pathway-against-pathway and pathway-against-mutation comparisons are not available for ontology entities.
Survival associations
This table summarizes Regulation of peptidyl-cysteine S-nitrosylation survival associations by molecular data type. RNA-level pathway activity shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each layer.
This table ranks reproducible pathway activity–survival associations across cancer types. High Regulation of peptidyl-cysteine S-nitrosylation activity shows favorable associations in THCA and LUAD, but unfavorable associations in DLBC, READ, UCS and LUSC. In the DLBC Kaplan–Meier curve the high-activity group declines faster, consistent with the unfavorable association (log-rank p < 0.001). DLBC ranks highest by sampling consensus for Regulation of peptidyl-cysteine S-nitrosylation.
This table summarizes Regulation of peptidyl-cysteine S-nitrosylation tumor–normal activity differences by data type. RNA-level activity shows significant tumor–normal differences in 14 cancer types, while mass-spec protein activity shows differences in 6. The strongest signals are in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal activity differences for the pathway. A positive fold-change indicates higher activity in tumor tissue. The pathway shows consistently lower tumor activity across HNSC, BLCA, LUSC, COAD, BRCA and LIHC. In the HNSC box plot, normal samples show higher pathway activity than tumor samples (log2 FC = −0.069, t-test p < 0.001).
This table shows molecular features associated with Regulation of peptidyl-cysteine S-nitrosylation pathway activity in patient tissues and cancer cell lines. In patient samples, pathway activity is most strongly linked to RNA and protein features, with the largest associated set in STAD. In cancer cell lines, RNA-expression features and functional dependencies dominate, with the largest set in LUNG_NSCLC_LUSC.